Skip to main content

Advertisement

SpringerLink
Log in

Predictive importance of galectin-3 for recurrence of non-small cell lung cancer

  • Original Article
  • Published:
General Thoracic and Cardiovascular Surgery Aims and scope Submit manuscript

Abstract

Objective

The predictive importance of galectin-3 in non-small cell lung cancer (NSCLC) has not been elucidated. We examined whether galectin-3 could serve as a predictor for tumor recurrence in NSCLC.

Methods

In 42 consecutive patients with NSCLC who underwent radical resection, galectin-3 expression in tumor cells was examined by immunohistochemistry. Galectin-3 levels in serum were assessed before surgery and 1 month after surgery by enzyme-linked immunosorbent assays.

Results

Higher expression of galectin-3 in tumor cells was associated significantly with lymphatic invasion (p = 0.049) and tumor recurrence (p = 0.001). The Kaplan–Meier curves for relapse-free survival after radical resection showed that patients with high expression of galectin-3 had significantly shorter relapse-free survival than those with low expression of galectin-3 (p < 0.001). The serum level of galectin-3 was not reduced after radical resection, and there was no significant correlation between the serum level of galectin-3 and recurrence.

Conclusions

Galectin-3 expression in tumor cells could serve as a predictive factor for recurrence, but serum level of galectin-3 is not useful for predicting NSCLC recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  Google Scholar 

  2. Lima JP, dos Santos LV, Sasse EC, Sasse AD. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. Eur J Cancer. 2009;45:601–7.

    Article  PubMed  Google Scholar 

  3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.

    Article  CAS  PubMed  Google Scholar 

  4. Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324–33.

    Article  PubMed  Google Scholar 

  5. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.

    Article  CAS  PubMed  Google Scholar 

  6. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.

    Article  PubMed  Google Scholar 

  7. Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol. 2011;6:1229–35.

    Article  PubMed  Google Scholar 

  8. Hughes RC. The galectin family of mammalian carbohydrate-binding molecules. Biochem Soc Trans. 1997;25:1194–8.

    Article  CAS  PubMed  Google Scholar 

  9. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008;10:e17.

    Article  PubMed  Google Scholar 

  10. Ahmed H, AlSadek DM. Galectin-3 as a potential target to prevent cancer metastasis. Clin Med Insights Oncol. 2015;9:113–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cardoso AC, Andrade LN, Bustos SO, Chammas R. Galectin-3 determines tumor cell adaptive strategies in stressed tumor microenvironments. Front Oncol. 2016;6:127.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57:5272–6.

    CAS  PubMed  Google Scholar 

  13. Nakahara S, Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev. 2007;26:605–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Szöke T, Kayser K, Trojan I, Kayser G, Furak J, Tiszlavicz L, et al. The role of microvascularization and growth/adhesion-regulatory lectins in the prognosis of non-small cell lung cancer in stage II. Eur J Cardiothorac Surg. 2007;31:783–7.

    Article  PubMed  Google Scholar 

  15. Chung LY, Tang SJ, Wu YC, Sun GH, Liu HY, Sun KH. Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin. Oncotarget. 2015;6:4936–52.

    PubMed  Google Scholar 

  16. Kuo HY, Hsu HT, Chen YC, Chang YW, Liu FT, Wu CW. Galectin-3 modulates the EGFR signalling-mediated regulation of Sox2 expression via c-Myc in lung cancer. Glycobiology. 2016;26:155–65.

    Article  CAS  PubMed  Google Scholar 

  17. Chan YC, Lin HY, Tu Z, Kuo YH, Hsu SD, Lin CH. Dissecting the structure-activity relationship of galectin-ligand interactions. Int J Mol Sci. 2018; 19.

  18. Dos Santos SN, Sheldon H, Pereira JX, Paluch C, Bridges EM, El-Cheikh MC, et al. Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation. Oncotarget. 2017;8:49484–501.

    PubMed  PubMed Central  Google Scholar 

  19. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res. 2000;6:1389–93.

    CAS  PubMed  Google Scholar 

  20. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, et al. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res. 2002;8:2570–5.

    CAS  PubMed  Google Scholar 

  21. Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res. 2000;6:4635–40.

    CAS  PubMed  Google Scholar 

  22. Ilmer M, Mazurek N, Gilcrease MZ, Byrd JC, Woodward WA, Buchholz TA, et al. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Res. 2016;18:97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Merseburger AS, Kramer MW, Hennenlotter J, Serth J, Kruck S, Gracia A, et al. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol. 2008;26:637–42.

    Article  CAS  PubMed  Google Scholar 

  24. Kosacka M, Piesiak P, Kowal A, Gołecki M, Jankowska R. Galectin-3 and cyclin D1 expression in non-small cell lung cancer. J Exp Clin Cancer Res. 2011;30:101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mathieu A, Saal I, Vuckovic A, Ransy V, Vereerstraten P, Kaltner H, et al. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2005;18:1264–71.

    Article  CAS  PubMed  Google Scholar 

  26. Puglisi F, Minisini AM, Barbone F, Intersimone D, Aprile G, Puppin C, et al. Galectin-3 expression in non-small cell lung carcinoma. Cancer Lett. 2004;212:233–9.

    Article  CAS  PubMed  Google Scholar 

  27. Gendy HE, Madkour B, Abdelaty S, Essawy F, Khattab D, Hammam O, et al. Diagnostic and prognostic significance of serum and tissue galectin 3 expression in patients with carcinoma of the bladder. Curr Urol. 2014;7:185–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Xie L, Ni WK, Chen XD, Xiao MB, Chen BY, He S, et al. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol. 2012;138:1035–43.

    Article  CAS  PubMed  Google Scholar 

  29. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res. 2008;38:1098–111.

    Article  CAS  PubMed  Google Scholar 

  30. Shimura T, Shibata M, Goda K, Nakajima T, Chida S, Noda M, et al. Elevated serum galectin-3 is associated with poor prognosis in patients with colorectal carcinoma. Ann Cancer Res Ther. 2016;24:12–6.

    Article  Google Scholar 

  31. Shimura T, Shibata M, Gonda K, Kofunato Y, Okada R, Ishigame T, et al. Significance of circulating galectin-3 in patients with pancreatobiliary cancer. Anticancer Res. 2017;37:4979–86.

    CAS  PubMed  Google Scholar 

  32. Gao X, Balan V, Tai G, Raz A. Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway. Oncotarget. 2014;5:2077–84.

    PubMed  PubMed Central  Google Scholar 

  33. Serizawa N, Tian J, Fukada H, Baghy K, Scott F, Chen X, et al. Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. Lab Invest. 2015;95:1145–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS KAKENHI, Grant numbers 16K19976 and 18K16415). The authors thank Mitsuaki Ishida for immunohistochemical analysis support.

Author information

Authors and Affiliations

  1. Department of Surgery, Shiga University of Medical Science, Seta- Tsukinowa, Otsu, Shiga, 520-2192, Japan

    Yoko Kataoka, Tomoyuki Igarashi, Yasuhiko Ohshio & Jun Hanaoka

  2. Department of General Thoracic Surgery, Kohka Public Hospital, Matsuo, Minakuchi, Koka, Shiga, 528-0074, Japan

    Yoko Kataoka & Takuya Fujita

Authors
  1. Yoko Kataoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoyuki Igarashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuhiko Ohshio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takuya Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Hanaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoko Kataoka.

Ethics declarations

Conflict of interest

Authors declared that they have no conflict of interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kataoka, Y., Igarashi, T., Ohshio, Y. et al. Predictive importance of galectin-3 for recurrence of non-small cell lung cancer. Gen Thorac Cardiovasc Surg 67, 704–711 (2019). https://doi.org/10.1007/s11748-019-01074-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11748-019-01074-x

Keywords

Search

Navigation